UC and cancer treatment

This content was last updated:14 Feb 2025

Subscriber

(For subscribers) Jessica Strode looks at universal credit (UC) provisions regarding claimants who are undergoing treatment for cancer by way of chemotherapy, radiotherapy or immunotherapy.

Issue: Issue 304 (February 2025)

You need a subscription to see this content. If you’re a subscriber, please log in to your account

Not yet a subscriber?

Find out more about our subscriptions and sign up

Not sure what you can access on AskCPAG?

Some of our content is free to access and other areas of the site are for subscribers only.

Find out more: What can I access on AskCPAG?

Advisory

Please be aware that welfare rights law and guidance change frequently. Older articles may be out of date.

Other articles from this issue

ESA to UC: run-on unlawfulness?

(For subscribers) Martin Williams considers whether those migrating from ESA to UC whose ESA includes contributory ESA as well as income-related ESA are discriminated against during their first assessment period.

Publication:Welfare Rights Bulletin, Issue 304 (February 2025)

Managed migration in 2025

Simon Osborne reviews where the managed migration to universal credit (UC) process has got to and what lies ahead in 2025.

Publication:Welfare Rights Bulletin, Issue 304 (February 2025)

Tax credits: loose ends

(For subscribers) As tax credits face the final curtain, there are a few outstanding issues that are worth mentioning. Mark Willis sets the stage.

Publication:Welfare Rights Bulletin, Issue 304 (February 2025)

Base text size -

UC and cancer treatment

Site admin